List of Emend drug patents
Emend is owned by Merck.
Emend contains Aprepitant.
Emend has a total of 1 drug patent out of which 0 drug patents have expired.
Emend was authorised for market use on 26 March, 2003.
Emend is available in capsule;oral dosage forms.
Emend can be used as prevention of postoperative nausea and vomiting; for the prevention of nausea and vomiting associated with chemotherapy.
The generics of Emend are possible to be released after 26 September, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(4 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 26 March, 2003
Treatment: Prevention of postoperative nausea and vomiting; For the prevention of nausea and vomiting associated with chemotherapy
Dosage: CAPSULE;ORAL
EMEND family patents
3
United States
1
ME
1
Yugoslavia
1
Poland
1
Dominican Republic
1
Canada
1
Georgia
1
Slovenia
1
Korea, Republic of
1
Ukraine
1
Brazil
1
Hong Kong
1
Taiwan
1
China
1
Iceland
1
Germany
1
Japan
1
Denmark
1
Croatia
1
Malaysia
1
Hungary
1
Argentina
1
Spain
1
Mexico
1
New Zealand
1
EA
1
Colombia
1
Australia
1
Norway
1
South Africa
1
Ecuador
1
Austria
1
Portugal
1
Israel
1
Jordan
1
Peru
1
European Union
Emend is owned by Msd Merck Co.
Emend contains Aprepitant.
Emend has a total of 1 drug patent out of which 0 drug patents have expired.
Emend was authorised for market use on 17 December, 2015.
Emend is available in for suspension;oral dosage forms.
Emend can be used as prevention of nausea and vomiting associated with chemotherapy (cinv).
The generics of Emend are possible to be released after 26 September, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(4 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
Dosage: FOR SUSPENSION;ORAL
EMEND family patents
3
United States
1
ME
1
Yugoslavia
1
Poland
1
Dominican Republic
1
Canada
1
Georgia
1
Slovenia
1
Korea, Republic of
1
Ukraine
1
Brazil
1
Hong Kong
1
Taiwan
1
China
1
Iceland
1
Germany
1
Japan
1
Denmark
1
Croatia
1
Malaysia
1
Hungary
1
Argentina
1
Spain
1
Mexico
1
New Zealand
1
EA
1
Colombia
1
Australia
1
Norway
1
South Africa
1
Ecuador
1
Austria
1
Portugal
1
Israel
1
Jordan
1
Peru
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic